CAMBRIDGE, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:
Barclays 26th Annual Global Healthcare Conference
Fireside Chat: Tuesday, March 12, 2024 at 4:35 pm ET
Location: Miami, FL
A live webcast and archived replay of the fireside chat will be available on the investors section of www.vorbio.com.
H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
Fireside Chat: Tuesday, March 26, 2024 at 2:30 pm ET
Location: Virtual
About Vor Bio
Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.
Contact:
Media & Investors
Sarah Spencer
+1 857-242-6076
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$0.65 |
| Daily Volume: | 122,512 |
| Market Cap: | US$80.950M |
March 20, 2025 January 08, 2025 December 27, 2024 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
